BioCentury | Apr 14, 2008
Finance

Ebb & Flow

...in cash. Dermatology company Excaliard , bone disease company Auxeris , oncology plays CGI and Kereos...
BioCentury | Mar 13, 2008
Distillery Techniques

This Week in Techniques

...their delivery pathways. Patent application filed in the U.S. for melittin-loaded nanoparticles for all applications; Kereos Inc....
BioCentury | Sep 11, 2006
Company News

Medior management update

...Penn. Business: Pulmonary Hired: Timothy Pelura as president and CEO, formerly chief technology officer of Kereos Inc. WIR...
BioCentury | Dec 19, 2005
Company News

Kereos management update

Kereos Inc. , St. Louis, Mo. Business: Cardiovascular, Diagnostic, Cancer Hired: G. Allen Nickols as VP of biology, formerly director of pharmacology at the Pfizer Inc.'s global R&D unit WIR Staff cancer Cardiovascular Diagnostic...
BioCentury | Dec 19, 2005
Company News

Kereos board of directors update

Kereos Inc. , St. Louis, Mo. Business: Cardiovascular, Diagnostic, Cancer Appointed: Gregory Johnson, managing director at Prolog Ventures; John Rice, managing partner at Triathlon Medical Ventures; and Martin Sanders, a venture partner at Charter Life Sciences...
BioCentury | Dec 12, 2005
Tools & Techniques

Visualizing new partnerships

...progression and response to treatment in patients suffering from coronary artery disease. In alliance with Kereos Inc....
BioCentury | Sep 21, 2005
Financial News

Kereos raises $19.5 million

...a chemotherapeutic that delivers paclitaxel directly to the site of angiogenesis, are in preclinical development. Kereos...
BioCentury | Jul 18, 2005
Finance

Ebb & Flow

...a portfolio company. Thus far, Prolog II has made three investments: cancer and cardiovascular company Kereos...
BioCentury | Sep 27, 2004
Company News

Kereos, The Dow Chemical Co. deal

...DOW granted Kereos exclusive commercialization rights to chelating molecules and chelate technology that Kereos will incorporate...
...portfolio for use with other applications. Financial terms were not disclosed. Under a 2002 deal, Kereos...
...Princeton, N.J.) rights to KI-0002 in exchange for an upfront fee, plus milestones and royalties. Kereos Inc....
BioCentury | Sep 21, 2004
Company News

Dow, Kereos imaging deal

...DOW granted Kereos exclusive commercialization rights to chelating molecules and chelate technology that Kereos will incorporate...
...portfolio for use with other applications. Financial terms were not disclosed. Under a 2002 deal, Kereos...
Items per page:
1 - 10 of 20
BioCentury | Apr 14, 2008
Finance

Ebb & Flow

...in cash. Dermatology company Excaliard , bone disease company Auxeris , oncology plays CGI and Kereos...
BioCentury | Mar 13, 2008
Distillery Techniques

This Week in Techniques

...their delivery pathways. Patent application filed in the U.S. for melittin-loaded nanoparticles for all applications; Kereos Inc....
BioCentury | Sep 11, 2006
Company News

Medior management update

...Penn. Business: Pulmonary Hired: Timothy Pelura as president and CEO, formerly chief technology officer of Kereos Inc. WIR...
BioCentury | Dec 19, 2005
Company News

Kereos management update

Kereos Inc. , St. Louis, Mo. Business: Cardiovascular, Diagnostic, Cancer Hired: G. Allen Nickols as VP of biology, formerly director of pharmacology at the Pfizer Inc.'s global R&D unit WIR Staff cancer Cardiovascular Diagnostic...
BioCentury | Dec 19, 2005
Company News

Kereos board of directors update

Kereos Inc. , St. Louis, Mo. Business: Cardiovascular, Diagnostic, Cancer Appointed: Gregory Johnson, managing director at Prolog Ventures; John Rice, managing partner at Triathlon Medical Ventures; and Martin Sanders, a venture partner at Charter Life Sciences...
BioCentury | Dec 12, 2005
Tools & Techniques

Visualizing new partnerships

...progression and response to treatment in patients suffering from coronary artery disease. In alliance with Kereos Inc....
BioCentury | Sep 21, 2005
Financial News

Kereos raises $19.5 million

...a chemotherapeutic that delivers paclitaxel directly to the site of angiogenesis, are in preclinical development. Kereos...
BioCentury | Jul 18, 2005
Finance

Ebb & Flow

...a portfolio company. Thus far, Prolog II has made three investments: cancer and cardiovascular company Kereos...
BioCentury | Sep 27, 2004
Company News

Kereos, The Dow Chemical Co. deal

...DOW granted Kereos exclusive commercialization rights to chelating molecules and chelate technology that Kereos will incorporate...
...portfolio for use with other applications. Financial terms were not disclosed. Under a 2002 deal, Kereos...
...Princeton, N.J.) rights to KI-0002 in exchange for an upfront fee, plus milestones and royalties. Kereos Inc....
BioCentury | Sep 21, 2004
Company News

Dow, Kereos imaging deal

...DOW granted Kereos exclusive commercialization rights to chelating molecules and chelate technology that Kereos will incorporate...
...portfolio for use with other applications. Financial terms were not disclosed. Under a 2002 deal, Kereos...
Items per page:
1 - 10 of 20